View Expired Tender

Get immediate access to tenders like the one below by subscribing now to Tenders Direct. We will set up your personalised profile and send you tender alerts direct to your mailbox as soon as they are published. You will also benefit from having access to historical tenders.

Notice Summary

Title:
UK-Southampton: 19/36 Antioxidant Supplements to Slow AMD Progression
Document Ref:
GB003ZM291132
Document Type:
Contract Notice - Other
Published By:
National Insttitute for Health Research
Date Published:
27 March 2019
Deadline Date:
31 July 2019
Document Source:
Framework/DPS:
No
Alert Profile:
Labels:

Notice Abstract

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic: 19/36 Antioxidant supplements to slow AMD progression Rationale: Age-related macular degeneration (AMD) is the most common form of macular degeneration and the most common cause of visual impairment in the developed world. Incidence and severity increase with advancing age and with an aging population AMD is a significant concern now and for the future. Treatments exist for the most severe forms of the disease but these are invasive and expensive so preventing or slowing progression of the disease before it gets to this stage is a priority. Lifestyle and nutrition have been linked to development and progression of AMD but to date no way of preventing these has been identified. There is some evidence that antioxidant vitamin and mineral supplements might slow progression of early AMD in people at high risk of developing advanced disease but the quality of the evidence is variable. The AREDS (Age-Related Eye Disease Study) and AREDS2 trials from the US dominate the literature and some authors and guidelines advise that the evidence from these is sufficient to recommend use of the AREDS2 supplement formula for slowing progression of AMD. However, NICE has recently concluded that limitations in the available evidence, including in the AREDS and AREDS2 studies, means no firm conclusions can be drawn on whether such antioxidant/vitamin supplements confer significant benefit (and without increasing risks) to patients with AMD. As such, NICE has called for an adequately powered, good quality randomised controlled trial to resolve the uncertainty that remains about the use of antioxidant/vitamin supplements in this population. Applicants will need to take account of baseline diet/nutritional status and food intake and if and how this can be recorded or measured throughout the period of the study.

Notice Details

CONTRACT NOTICE – NATIONAL

SERVICES

1 Authority Details

1.1

Authority Name and Address

National Insttitute for Health Research
N/A
Southampton UK
N/A N/A
N/A

1.2

Address from which documentation may be obtained

As in 1.1

1.3

Completed documents must be returned to:

As in 1.1

2 Contract Details

2.1

Title

19/36 Antioxidant Supplements to Slow AMD Progression

2.2

Description of the goods or services required

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic:

19/36 Antioxidant supplements to slow AMD progression

Rationale:

Age-related macular degeneration (AMD) is the most common form of macular degeneration and

the most common cause of visual impairment in the developed world. Incidence and severity

increase with advancing age and with an aging population AMD is a significant concern now and

for the future.

Treatments exist for the most severe forms of the disease but these are invasive and expensive so

preventing or slowing progression of the disease before it gets to this stage is a priority. Lifestyle

and nutrition have been linked to development and progression of AMD but to date no way of

preventing these has been identified.

There is some evidence that antioxidant vitamin and mineral supplements might slow progression

of early AMD in people at high risk of developing advanced disease but the quality of the evidence

is variable. The AREDS (Age-Related Eye Disease Study) and AREDS2 trials from the US

dominate the literature and some authors and guidelines advise that the evidence from these is

sufficient to recommend use of the AREDS2 supplement formula for slowing progression of AMD.

However, NICE has recently concluded that limitations in the available evidence, including in the

AREDS and AREDS2 studies, means no firm conclusions can be drawn on whether such

antioxidant/vitamin supplements confer significant benefit (and without increasing risks) to patients

with AMD. As such, NICE has called for an adequately powered, good quality randomised

controlled trial to resolve the uncertainty that remains about the use of antioxidant/vitamin

supplements in this population. Applicants will need to take account of baseline diet/nutritional

status and food intake and if and how this can be recorded or measured throughout the period of

the study.

2.3

Notice Coding and Classification

2.4

Total quantity or scope of tender

3 Conditions for Participation

3.1

Minimum standards and qualification required

4 Administrative Information

4.1

Type of Procedure

The procedure type is unknown.

4.2

Reference number attributed to the notice by the contracting authority

19/36

4.3

Time Limits

   31-07-2019  Time 13:00

4.5

Language or languages in which tenders or requests to participate can be drawn up

EN 

4.6

Tender Submission Postbox

5 Other Information

5.1

Additional Information

Please visit the following portal to view this notice:

https://www.nihr.ac.uk/funding-and-support/funding-opportunities/1936-antioxidant-supplements-to-slow-amd-progression/10564

The deadline for applications is 1pm, 31 July 2019.

(MT Ref:291132)

5.2

Additional Documentation

5.3

Publication date of this notice

 27-03-2019

Current Notes